文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

达尔西利联合吡咯替尼及内分泌治疗用于ER阳性、HER2阳性晚期乳腺癌女性:一项前瞻性、多中心、单臂、2期试验

Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial.
PubMed 文献 · PLoS Med · 2025-07-31

这项前瞻性、多中心、单臂2期试验评估达尔西利联合吡咯替尼及内分泌治疗用于ER阳性、HER2阳性晚期乳腺癌一线或二线治疗的活性与安全性。48例可评估患者中,研究者确认的客观缓解率为70.2%(95%CI [55.1, 82.7]),中位无进展生存期22.0个月(95%CI [16.6, 26.6])。联合方案显示出抗肿瘤活性且安全性可控,作者认为支持进一步评估其作为潜在替代方案。

要点

  • 48例可评估患者中,客观缓解率为70.2%(95%CI [55.1, 82.7]),疾病控制率为100%(95%CI [92.5, 100])。
  • 中位无进展生存期22.0个月(95%CI [16.6, 26.6]),中位缓解持续时间22.3个月(95%CI [16.4, 26.9])。
  • 3级和4级治疗相关不良事件分别发生于68.8%和12.5%的患者,主要为骨髓抑制。

核心结论

  • 达尔西利联合吡咯替尼及内分泌治疗这一非静脉、免化疗方案在ER阳性、HER2阳性晚期乳腺癌一线治疗中显示出抗肿瘤活性且安全性可控,作者认为支持进一步评估其作为潜在替代方案。

研究设计与样本

  • 前瞻性、研究者发起的多中心、单臂、2期临床试验(PLEASURABLE),在中国六家中心开展。
  • 2019年8月1日至2022年11月28日入组ER阳性、HER2阳性晚期乳腺癌患者,共筛查51例,48例可评估(中位年龄52.5岁,范围29-74)。
  • 患者接受达尔西利125 mg每日一次(每28天周期第1-21天)和吡咯替尼320 mg每日一次,联合由医生选择的内分泌治疗(来曲唑或氟维司群)。
  • 主要终点为客观缓解率,次要终点包括无进展生存期、缓解持续时间、疾病控制率、临床获益率、安全性、血浆药代动力学和生物标志物分析。
  • 疗效在改良意向治疗人群(至少有一次基线后肿瘤评估的患者)中分析,安全性在所有至少接受一剂治疗的患者中评估。

主要发现

  • 31例(64.6%)有既往HER2靶向治疗史,37例(77.1%)有既往内分泌治疗史;30例(62.5%)和18例(37.5%)分别作为晚期乳腺癌一线和二线HER2靶向治疗接受研究方案。
  • 截至2024年12月11日数据截止,6例失访,中位随访27.3个月(四分位距24.8-30.5)。
  • 研究者确认的客观缓解率为70.2%(95%CI [55.1, 82.7]),疾病控制率100%(95%CI [92.5, 100]),临床获益率87.2%(95%CI [74.3, 95.2])。
  • 中位无进展生存期22.0个月(95%CI [16.6, 26.6]),中位缓解持续时间22.3个月(95%CI [16.4, 26.9])。
  • 未观察到新的安全性信号,无治疗相关死亡,仅1例(2.1%)1级脱发,无间质性肺病;3级和4级治疗相关不良事件分别发生于68.8%和12.5%的患者,主要为骨髓抑制;药代动力学分析显示达尔西利或吡咯替尼在治疗期间无主要药物蓄积。

关键数值与推荐

  • 客观缓解率70.2%(95%CI [55.1, 82.7]),疾病控制率100%(95%CI [92.5, 100]),临床获益率87.2%(95%CI [74.3, 95.2])。
  • 中位无进展生存期22.0个月(95%CI [16.6, 26.6]),中位缓解持续时间22.3个月(95%CI [16.4, 26.9])。
  • 3级治疗相关不良事件发生率68.8%,4级治疗相关不良事件发生率12.5%。
  • 在检测到BRCA突变(n=2)或初始两个周期内68Ga-HER2 affibody摄取增高(n=2)的三例患者中未观察到客观缓解。

临床怎么用

  • 作者认为,达尔西利联合吡咯替尼及内分泌治疗这一非静脉、免化疗方案在ER阳性、HER2阳性晚期乳腺癌一线治疗中显示出抗肿瘤活性且安全性可控,支持进一步评估其作为潜在替代方案。

局限性

  • 原文指出,由于患者队列有限以及探索性分析中样本量小,本研究结果应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combination of HER2-targeted therapy and endocrine therapy offers a more tolerable alternative to HER2-targeted chemotherapy regimens for estrogen receptor (ER)-positive, HER2-positive advanced breast cancer (ABC), but with compromised efficacy. The addition of cyclin-dependent kinase 4/6 (CDK4/6) inhibition may enhance the durability of anti-tumor responses, offering a potential chemotherapy-sparing alternative, although its role in the frontline setting remains uncertain. We performed a multicenter, single-arm, phase 2 clinical trial (PLEASURABLE) to assess the activity and safety of combining dalpiciclib with pyrotinib and endocrine therapy in patients receiving first- or second-line treatment for ER-positive and HER2-positive ABC. METHODS AND FINDINGS: We enrolled patients with ER-positive and HER2-positive ABC between August 1, 2019, and November 28, 2022 in this prospective, investigator-initiated trial conducted at six centers in China. Patients received dalpiciclib (125 mg once daily, on days 1-21 of each 28-day cycle) and pyrotinib (320 mg once daily) plus endocrine therapy determined by the physician's choice (letrozole or fulvestrant). The primary endpoint was the objective response rate (ORR), while secondary endpoints included progression-free survival (PFS), duration of response (DOR), disease control rate (DCR), clinical benefit rate (CBR), safety, plasma pharmacokinetics (PK), and biomarker analysis. Efficacy was analyzed in the modified intention-to-treat population, comprising patients with at least one post-baseline tumor assessment. Safety was assessed in all patients who received at least one dose. A total of 51 patients were screened, and 48 were evaluable (median age was 52.5 years [range, 29-74]); 31 (64.6%) had prior HER2-target therapy, and 37 (77.1%) had received prior endocrine therapy. Thirty (62.5%) and 18 (37.5%) patients received the study treatment as first- and second-line HER2-targeted treatment for ABC, respectively. As of the data cutoff on December 11, 2024, six patients were lost to follow-up, and the median follow-up was 27.3 months (interquartile range, 24.8-30.5). The investigator confirmed ORR was 70.2% (95% CI [55.1, 82.7]), with a DCR of 100% (95% CI [92.5, 100]) and a CBR of 87.2% (95% CI [74.3, 95.2]). The median PFS was 22.0 months (95% CI [16.6, 26.6]), and the median DOR was 22.3 months (95% CI [16.4, 26.9]). No new safety signals were observed, and no treatment-related deaths occurred with only one (2.1%) grade 1 alopecia and no interstitial lung disease. Grade 3 or 4 treatment-related adverse events occurred in 68.8% and 12.5% of patients, respectively, mostly myelosuppression. PK analysis showed no major drug accumulation for dalpiciclib or pyrotinib over the treatment period. Of interest, no objective response was observed in three patients with detected BRCA mutations (n = 2) or increased 68Ga-HER2 affibody uptake over the initial two cycles (n = 2). The findings of this study should be interpreted with caution due to the limited patient cohort and sample size in exploratory analyses. CONCLUSIONS: The non-intravenous, chemotherapy-sparing combination of dalpiciclib, pyrotinib, and endocrine therapy demonstrated anti-tumor activity with a manageable safety profile in the frontline treatment of ER-positive, HER2-positive ABC, supporting its further evaluation as a potential alternative. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03772353.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Zhang J, Meng Y, Wang B, et al. Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial. PLoS Med. 2025. PMID: 40743286. doi:10.1371/journal.pmed.1004669

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。